Dysregulation of G9a,a histone-lysine N-methyltransferase,has been observed in Alzheimer’s disease and has been correlated with increased levels of chronic inflammation and oxidative stress.Likewise,microRNAs are inv...Dysregulation of G9a,a histone-lysine N-methyltransferase,has been observed in Alzheimer’s disease and has been correlated with increased levels of chronic inflammation and oxidative stress.Likewise,microRNAs are involved in many biological processes and diseases playing a key role in pathogenesis,especially in multifactorial diseases such as Alzheimer’s disease.Therefore,our aim has been to provide partial insights into the interconnection between G9a,microRNAs,oxidative stress,and neuroinflammation.To better understand the biology of G9a,we compared the global microRNA expression between senescence-accelerated mouse-prone 8(SAMP8)control mice and SAMP8 treated with G9a inhibitor UNC0642.We found a downregulation of miR-128 after a G9a inhibition treatment,which interestingly binds to the 3′untranslated region(3′-UTR)of peroxisome-proliferator activator receptor γ(PPARG)mRNA.Accordingly,Pparg gene expression levels were higher in the SAMP8 group treated with G9a inhibitor than in the SAMP8 control group.We also observed modulation of oxidative stress responses might be mainly driven Pparg after G9a inhibitor.To confirm these antioxidant effects,we treated primary neuron cell cultures with hydrogen peroxide as an oxidative insult.In this setting,treatment with G9a inhibitor increases both cell survival and antioxidant enzymes.Moreover,up-regulation of PPARγby G9a inhibitor could also increase the expression of genes involved in DNA damage responses and apoptosis.In addition,we also described that the PPARγ/AMPK axis partially explains the regulation of autophagy markers expression.Finally,PPARγ/GADD45αpotentially contributes to enhancing synaptic plasticity and neurogenesis after G9a inhibition.Altogether,we propose that pharmacological inhibition of G9a leads to a neuroprotective effect that could be due,at least in part,by the modulation of PPARγ-dependent pathways by miR-128.展开更多
目的利用药效团模型和分子对接方法对商业化合物库ChemDiv中的G9afocused-libraries进行筛选,希望发现新骨架结构的G9a抑制剂。方法首先,使用Discovery studio 3.1软件分别构建基于配体的药效团模型和基于配体-受体复合物的药效团模型,...目的利用药效团模型和分子对接方法对商业化合物库ChemDiv中的G9afocused-libraries进行筛选,希望发现新骨架结构的G9a抑制剂。方法首先,使用Discovery studio 3.1软件分别构建基于配体的药效团模型和基于配体-受体复合物的药效团模型,并根据构建的2个模型再重新定义2个新的药效团模型。然后,构建测试集并测试药效团模型的预测能力。最后,选取最优药效团模型对G9afocused-libraries进行筛选,对筛选出的化合物使用CDOCKER分子对接进行分析与评价。结果测试结果显示,所构建的药效团模型具有一定的预测能力,通过该药效团筛选得到了2个结构新颖的潜在的G9a抑制剂。结论所构建的药效团模型具有一定的可靠性,虚拟筛选发现的G9a抑制剂还需进一步的实验证明。展开更多
基金supported by the Ministerio de Economía,Industria y Competitividad(Agencia Estatal de Investigación,AEI,to CGF and MP)Fondo Europeo de Desarrollo Regional(MINECO-FEDER)(PID2022-139016OA-I00,PDC2022-133441-I00,to CGF and MP),Generalitat de Catalunya(2021 SGR 00357+3 种基金to CGF and MP)co-financed by Secretaria d’Universitats i Recerca del Departament d’Empresai Coneixement de la Generalitat de Catalunya 2021(Llavor 00086,to CGF)the recipient of an Alzheimer’s Association Research Fellowship(AARF-21-848511)the Agència de Gestiód’Ajuts Universitaris i de Recerca(AGAUR)for her FI-SDUR fellowship(2021FISDU 00182).
文摘Dysregulation of G9a,a histone-lysine N-methyltransferase,has been observed in Alzheimer’s disease and has been correlated with increased levels of chronic inflammation and oxidative stress.Likewise,microRNAs are involved in many biological processes and diseases playing a key role in pathogenesis,especially in multifactorial diseases such as Alzheimer’s disease.Therefore,our aim has been to provide partial insights into the interconnection between G9a,microRNAs,oxidative stress,and neuroinflammation.To better understand the biology of G9a,we compared the global microRNA expression between senescence-accelerated mouse-prone 8(SAMP8)control mice and SAMP8 treated with G9a inhibitor UNC0642.We found a downregulation of miR-128 after a G9a inhibition treatment,which interestingly binds to the 3′untranslated region(3′-UTR)of peroxisome-proliferator activator receptor γ(PPARG)mRNA.Accordingly,Pparg gene expression levels were higher in the SAMP8 group treated with G9a inhibitor than in the SAMP8 control group.We also observed modulation of oxidative stress responses might be mainly driven Pparg after G9a inhibitor.To confirm these antioxidant effects,we treated primary neuron cell cultures with hydrogen peroxide as an oxidative insult.In this setting,treatment with G9a inhibitor increases both cell survival and antioxidant enzymes.Moreover,up-regulation of PPARγby G9a inhibitor could also increase the expression of genes involved in DNA damage responses and apoptosis.In addition,we also described that the PPARγ/AMPK axis partially explains the regulation of autophagy markers expression.Finally,PPARγ/GADD45αpotentially contributes to enhancing synaptic plasticity and neurogenesis after G9a inhibition.Altogether,we propose that pharmacological inhibition of G9a leads to a neuroprotective effect that could be due,at least in part,by the modulation of PPARγ-dependent pathways by miR-128.
文摘目的利用药效团模型和分子对接方法对商业化合物库ChemDiv中的G9afocused-libraries进行筛选,希望发现新骨架结构的G9a抑制剂。方法首先,使用Discovery studio 3.1软件分别构建基于配体的药效团模型和基于配体-受体复合物的药效团模型,并根据构建的2个模型再重新定义2个新的药效团模型。然后,构建测试集并测试药效团模型的预测能力。最后,选取最优药效团模型对G9afocused-libraries进行筛选,对筛选出的化合物使用CDOCKER分子对接进行分析与评价。结果测试结果显示,所构建的药效团模型具有一定的预测能力,通过该药效团筛选得到了2个结构新颖的潜在的G9a抑制剂。结论所构建的药效团模型具有一定的可靠性,虚拟筛选发现的G9a抑制剂还需进一步的实验证明。
